Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.45 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PHGDH | O43175 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25431128 | 1.00 | POLB (0.59) | POLBSMN1; SMN2HRH3HRH4HRH1 | |
| SCHEMBL31428828 | 0.85 | POLB (0.59) | POLBSMN1; SMN2HRH3HRH4KMT2A | |
| SCHEMBL25376559 | 0.84 | POLB (0.55) | POLBSMN1; SMN2HRH3HRH4HRH1 | |
| SCHEMBL31428559 | 0.82 | POLB (0.56) | POLBSMN1; SMN2HRH3HRH4KMT2A | |
| SCHEMBL30163500 | 0.82 | POLB (0.56) | POLBSMN1; SMN2HRH3HRH4KMT2A | |
| SCHEMBL3369566 | 0.80 | HRH4 (0.59) | POLBSMN1; SMN2HRH3HRH4KMT2A | |
| SCHEMBL18889291 | 0.79 | HRH4 (0.76) | POLBSMN1; SMN2HRH3HRH4HRH1 | |
| SCHEMBL2770082 | 0.75 | HRH4 (0.71) | POLBSMN1; SMN2HRH3HRH4KMT2A | |
| SCHEMBL30189254 | 0.74 | F7 (0.56) | KMT2AMEN1PIN1 | |
| SCHEMBL1202548 | 0.74 | F7 (0.56) | KMT2AMEN1PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4482583-B1 | ZWITTERIONIC ANTIBACTERIAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2026-04-01 | — | — | EP | disclosed |
| US-20250179066-A1 | ZWITTERIONIC ANTIBACTERIAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-06-05 | — | — | US | disclosed |
| EP-4482583-A1 | ZWITTERIONIC ANTIBACTERIAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2025-01-01 | — | — | EP | disclosed |
| WO-2023161316-A1 | ZWITTERIONIC ANTIBACTERIAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179066-A1 | ZWITTERIONIC ANTIBACTERIAL COMPOUNDS | MRPL21, WIZ, CFTR | POLB 2586/4885SMN1; SMN2 3678/4885HRH3 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.